39. Toxic epidermal necrolysis Clinical trials / Disease details
Clinical trials : 13 / Drugs : 19 - (DrugBank : 8) / Drug target genes : 11 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04711200 (ClinicalTrials.gov) | September 2022 | 30/11/2020 | LYell SYndrome MEsenchymal Stromal Cells Treatment | Mesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open Trial | Epidermal Necrolysis;Lyell Syndrome;Toxic Epidermal Necrolysis;Overlap Syndrome;Mesenchymal Stromal Cells;Adipose Derived Stromal Cells | Drug: Adipose derived stromal cells intravenously injected | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | 75 Years | All | 15 | Phase 1/Phase 2 | NULL |